HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nikhil C Munshi Selected Research

Cytotoxins (Cytolysins)

4/2009CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
7/2007Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
7/2007Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.
7/2004In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nikhil C Munshi Research Topics

Disease

207Multiple Myeloma
05/2024 - 01/2002
108Neoplasms (Cancer)
04/2024 - 07/2002
11Hematologic Neoplasms (Hematological Malignancy)
01/2022 - 10/2003
10Waldenstrom Macroglobulinemia (Macroglobulinemia)
09/2022 - 07/2004
6Genomic Instability
11/2023 - 01/2018
6Adenocarcinoma
11/2022 - 05/2004
6Residual Neoplasm
01/2020 - 07/2013
5Chromosomal Instability (Chromosome Stability)
01/2023 - 01/2002
5Colorectal Neoplasms (Colorectal Cancer)
11/2022 - 08/2012
5Lymphoma (Lymphomas)
01/2022 - 07/2006
5Carcinogenesis
01/2021 - 02/2011
5Paraproteinemias (Monoclonal Gammopathy)
01/2020 - 03/2007
4Colonic Neoplasms (Colon Cancer)
11/2022 - 01/2014
4Plasmacytoma
09/2007 - 09/2002
3Breast Neoplasms (Breast Cancer)
11/2022 - 03/2011
3Infections
02/2022 - 05/2002
3Fatigue
01/2022 - 08/2010
3Peripheral Nervous System Diseases (PNS Diseases)
01/2018 - 07/2009
3Monoclonal Gammopathy of Undetermined Significance
01/2018 - 10/2009
3Bone Diseases (Bone Disease)
01/2016 - 07/2009
3Leukemia
01/2016 - 03/2007
3Bone Resorption
08/2012 - 10/2007
3Human Influenza (Influenza)
03/2011 - 06/2003

Drug/Important Bio-Agent (IBA)

37Bortezomib (Velcade)FDA Link
03/2024 - 09/2002
27Lenalidomide (CC 5013)FDA Link
10/2023 - 12/2004
22Dexamethasone (Maxidex)FDA LinkGeneric
10/2023 - 02/2002
21Proteasome InhibitorsIBA
03/2024 - 10/2002
17Proteins (Proteins, Gene)FDA Link
03/2024 - 05/2002
16AntigensIBA
04/2024 - 06/2003
13Interleukin-6 (Interleukin 6)IBA
08/2016 - 01/2002
12CytokinesIBA
03/2024 - 01/2002
10Telomerase (Telomerase Reverse Transcriptase)IBA
03/2024 - 01/2002
10DNA (Deoxyribonucleic Acid)IBA
01/2023 - 03/2003
9Monoclonal AntibodiesIBA
03/2024 - 07/2005
9B-Cell Maturation AntigenIBA
03/2024 - 07/2006
9Chimeric Antigen ReceptorsIBA
01/2023 - 01/2021
9MicroRNAs (MicroRNA)IBA
01/2020 - 10/2010
9Thalidomide (Thalomid)FDA Link
11/2019 - 06/2002
8Melphalan (Alkeran)FDA LinkGeneric
05/2024 - 07/2002
8Biomarkers (Surrogate Marker)IBA
01/2023 - 10/2007
8NF-kappa B (NF-kB)IBA
04/2010 - 08/2002
7Immunomodulating AgentsIBA
11/2021 - 04/2009
6Histone Deacetylases (Histone Deacetylase)IBA
04/2024 - 10/2003
6Histone Deacetylase InhibitorsIBA
04/2024 - 05/2003
6idecabtagene vicleucelIBA
01/2023 - 01/2021
6Immunoglobulin G (IgG)IBA
11/2014 - 07/2005
5Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
03/2024 - 01/2003
5bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA
10/2023 - 05/2005
5Proteasome Endopeptidase Complex (Proteasome)IBA
01/2023 - 10/2002
5Long Noncoding RNAIBA
01/2023 - 01/2018
5Immunoconjugates (Immunoconjugate)IBA
11/2021 - 07/2004
5Peptides (Polypeptides)IBA
01/2019 - 06/2012
4Immunoglobulins (Immunoglobulin)IBA
01/2023 - 01/2006
4UbiquitinIBA
01/2023 - 08/2017
4Immunoglobulin M (IgM)IBA
11/2021 - 12/2008
4EnzymesIBA
08/2017 - 10/2003
4Messenger RNA (mRNA)IBA
10/2015 - 08/2008
4perifosineIBA
04/2010 - 05/2006
4Cytotoxins (Cytolysins)IBA
04/2009 - 07/2004
4GlucocorticoidsIBA
12/2007 - 06/2005
4Insulin-Like Growth Factor I (IGF-1)IBA
02/2003 - 08/2002
3OligonucleotidesIBA
03/2024 - 02/2002
3dacetuzumabIBA
03/2024 - 04/2004
3Insulin (Novolin)FDA Link
03/2024 - 08/2002
3Small Interfering RNA (siRNA)IBA
11/2023 - 07/2005
3Alkylating AgentsIBA
01/2023 - 07/2007
3Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2023 - 08/2005
3RNA (Ribonucleic Acid)IBA
12/2022 - 10/2003
3pomalidomideIBA
11/2021 - 03/2013
3trans-crotonin (CTN)IBA
01/2020 - 01/2018
3LigandsIBA
01/2019 - 07/2006
3CD40 Ligand (CD40L)IBA
01/2018 - 07/2005
3Transcription Factors (Transcription Factor)IBA
01/2017 - 02/2011
3Zoledronic Acid (Zometa)FDA Link
11/2014 - 09/2009
3Sirolimus (Rapamycin)FDA Link
04/2010 - 12/2004
3Antineoplastic Agents (Antineoplastics)IBA
04/2010 - 09/2002
3AntibodiesIBA
01/2008 - 01/2004
3Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
10/2007 - 06/2005
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
07/2007 - 07/2006
3ParaproteinsIBA
08/2005 - 07/2004
3Doxorubicin (Adriamycin)FDA LinkGeneric
07/2005 - 07/2002
2LNA-i-miR-221IBA
05/2024 - 03/2016
2citarinostatIBA
04/2024 - 01/2018
2CalreticulinIBA
03/2024 - 01/2021
2telomerase RNA (bTR)IBA
03/2024 - 10/2003
2phosphoramidic acidIBA
03/2024 - 10/2003
2GRN163IBA
03/2024 - 10/2003
2Cyclophilins (Cyclophilin)IBA
01/2024 - 06/2015
2Phosphotransferases (Kinase)IBA
11/2023 - 12/2004
2Cisplatin (Platino)FDA LinkGeneric
01/2023 - 01/2021
2A-Form DNA (A-DNA)IBA
01/2023 - 11/2022
2Recombinases (Recombinase)IBA
11/2022 - 01/2020
2venetoclaxIBA
01/2022 - 11/2021
2VaccinesIBA
01/2022 - 07/2013

Therapy/Procedure

70Therapeutics
10/2023 - 08/2002
12Drug Therapy (Chemotherapy)
03/2024 - 05/2004
12Immunotherapy
03/2024 - 06/2003
7Stem Cell Transplantation
01/2022 - 02/2007
4Transplantation
01/2022 - 03/2007
3Chemoprevention
12/2010 - 05/2004